In addition, therapeutic drugs targeting CSF‐1 secretion in melanoma have been shown to reduce the expansion of the monocyte–myeloid‐derived suppressor cells subset and macrophage conversion, reprogram regulatory myeloid cells, and reduce tumor progression [166]. This evidence concerns the gene CSF1 and neoplasm.